Format

Send to

Choose Destination
Endocrinol Metab (Seoul). 2019 Mar;34(1):53-62. doi: 10.3803/EnM.2019.34.1.53.

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement.

Author information

1
Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, Korea.
2
Department of Endocrinology, Yonsei University College of Medicine, Seoul, Korea.
3
Division of Endocrinology, Department of Internal Medicine, Gachon University College of Medicine, Incheon, Korea.
4
Division of Endocrinology and Metabolism, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, Korea.
5
Division of Endocrinology and Metabolism, Department of Medicine, Konkuk University School of Medicine, Seoul, Korea.
6
Department of Internal Medicine, Cheil General Hospital & Women's Healthcare Center, Dankook University College of Medicine, Seoul, Korea.
7
Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
8
Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
9
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
10
Division of Geriatrics, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
11
Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Chonbuk National University and Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea.
12
Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea.
13
Department of Internal Medicine, Dongguk University College of Medicine, Gyeongju, Korea.
14
Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea.
15
Department of Internal Medicine, Inje University College of Medicine, Busan, Korea.
16
Division of Endocrinology, Department of Internal Medicine, Wonkwang University Sanbon Hospital, Wonkwang University School of Medicine, Gunpo, Korea.
17
Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, Korea.
18
Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea. dongsun@hanyang.ac.kr.
19
Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, Bucheon, Korea. drangel@sejongh.co.kr.

Abstract

The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.

KEYWORDS:

Acromegaly; Lanreotide; Octreotide; Pasireotide; Somatostatin analogues

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Publication type

Publication type

Supplemental Content

Full text links

Icon for Korean Endocrine Society Icon for PubMed Central
Loading ...
Support Center